Device type · NHX
Antibodies, Anti-Cyclic Citrullinated Peptide (Ccp)
Last checked: Nov 19, 2026Source: openFDAMethods & limitations
Product code
NHX
Immunology
Device class
Class II
FDA decisions since 2015
2
510(k), De Novo and PMA
Adverse event reports
1
Received Nov 1, 2025 to Nov 19, 2026
How FDA classifies it
- Device type
- Antibodies, Anti-Cyclic Citrullinated Peptide (Ccp)
- Product code
- NHX
- Device class
- Class II
- Review panel
- Immunology
- Regulation
- 21 CFR 866.5775
- Specialty
- Laboratory Medicine & Pathology
- FDA record
- Classification database entry for NHX
Latest FDA decisions
Axis-Shield Diagnostics Limited
K153551 · Decided Aug 4, 2016 · 237 days after receipt
Device type: Antibodies, Anti-Cyclic Citrullinated Peptide (Ccp) (NHX) · Laboratory Medicine & Pathology
K143754 · Decided Sep 21, 2015 · 264 days after receipt
Device type: Antibodies, Anti-Cyclic Citrullinated Peptide (Ccp) (NHX) · Laboratory Medicine & Pathology
Reports received
1
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
1
100% of reports
Injury reports
0
0.0% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 0 | 0 | 0 |
| Jan 24 | 1 | 0 | 0 | 0 |
| Feb 24 | 0 | 0 | 0 | 0 |
| Mar 24 | 0 | 0 | 0 | 0 |
| Apr 24 | 0 | 0 | 0 | 0 |
| May 24 | 0 | 0 | 0 | 0 |
| Jun 24 | 0 | 0 | 0 | 0 |
| Jul 24 | 1 | 0 | 0 | 0 |
| Aug 24 | 1 | 0 | 0 | 0 |
| Sep 24 | 0 | 0 | 0 | 0 |
| Oct 24 | 1 | 0 | 0 | 0 |
| Nov 24 | 0 | 0 | 0 | 0 |
| Dec 24 | 0 | 0 | 0 | 0 |
| Jan 25 | 0 | 0 | 0 | 0 |
| Feb 25 | 0 | 0 | 0 | 0 |
| Mar 25 | 0 | 0 | 0 | 0 |
| Apr 25 | 0 | 0 | 0 | 0 |
| May 25 | 0 | 0 | 0 | 0 |
| Jun 25 | 0 | 0 | 0 | 0 |
| Jul 25 | 0 | 0 | 0 | 0 |
| Aug 25 | 0 | 0 | 0 | 0 |
| Sep 25 | 1 | 0 | 0 | 0 |
| Oct 25 | 1 | 0 | 0 | 0 |
| Nov 25 | 0 | 0 | 0 | 0 |
| Dec 25 | 1 | 0 | 0 | 0 |
| Jan 26 | 0 | 0 | 0 | 0 |
| Feb 26 | 0 | 0 | 0 | 0 |
| Mar 26 | 0 | 0 | 0 | 0 |
| Apr 26 | 0 | 0 | 0 | 0 |
| May 26 | 0 | 0 | 0 | 0 |
| Jun 26 | 0 | 0 | 0 | 0 |
| Jul 26 | 0 | 0 | 0 | 0 |
| Aug 26 | 0 | 0 | 0 | 0 |
| Sep 26 | 0 | 0 | 0 | 0 |
| Oct 26 | 0 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
- Incorrect, Inadequate or Imprecise Result or Readings1
- Non Reproducible Results1
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
- No Clinical Signs, Symptoms or Conditions1
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- ABBOTT DIAGNOSTICS ALINITY I ANTI-CCPS REAGENT.Open, Classified
Mckesson Medical-Surgical Inc. Corporate Office
Z-1853-2025 · Started Apr 24, 2025 · Posted by FDA May 27, 2025
Reason given: transit delays of certain cold chain products due to severe thunderstorms which may caused the products to be stored outside the recommended labeled storage conditions. This failure could increase the probability of an incorrect test result or a delayed test result.
Cause as FDA categorized it: Storage
- BioPlex 2200, Anti-CCP Reagent Pack, REF 665-3250, IVDOpen, Classified
Z-1377-2023 · Started Feb 21, 2023 · Posted by FDA Apr 12, 2023
Reason given: Bio-Rad received four customer complaints from 11/30/2022 to 12/21/2022 on BioPlex 2200 Anti-CCP Kit (Lot 301481) stating that results were discrepant while performing lot-to-lot validation against previous lots. Internal testing at Bio-Rad has demonstrated that Lot No. 301481 exhibits a specificity of 94.5% (95% CI...
Cause as FDA categorized it: Under Investigation by firm
- BioPlex 2200, Anti-CCP Calibrator Set, REF 663-3200, IVDOpen, Classified
Z-1378-2023 · Started Feb 21, 2023 · Posted by FDA Apr 12, 2023
Reason given: Bio-Rad received four customer complaints from 11/30/2022 to 12/21/2022 on BioPlex 2200 Anti-CCP Kit (Lot 301481) stating that results were discrepant while performing lot-to-lot validation against previous lots. Internal testing at Bio-Rad has demonstrated that Lot No. 301481 exhibits a specificity of 94.5% (95% CI...
Cause as FDA categorized it: Under Investigation by firm
6 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.